Get email updates from SABCSMeetingNews.org
Subscribe to get regular news updates from SABCS.org and SABCS Meeting News.
DECEMBER 6–10, 2022
Henry B. Gonzalez Convention Center
San Antonio, TX
Komal Jhaveri, MD, FACP, will moderate discussions about current controversies in translational medicine for breast cancer.
Seema A. Khan, MD, will lead a session on Thursday afternoon looking at evolving evidence on managing patients at moderate genetic breast cancer risk.
An educational session on Thursday, moderated by Bora Lim, MD, will explore the diagnosis and treatment of less common, more challenging, breast cancers.
Ariella Hanker, PhD, and Sarat Chandarlapaty, MD, PhD, preview their presentations on inhibitors, set for Thursday afternoon.
Geoffrey M. Wahl, PhD, will receive the Brinker Award for Scientific Distinction in Basic Science on Thursday, and will deliver the lecture “Guardian at the Gates: Genome Stability, Cell State, Plasticity, and Breast Cancer.”
Tuesday’s General Session included data on race and clinical outcomes in patients with similar 21-gene recurrence scores, the evaluation of the Breast Cancer Index in premenopausal women with early-stage HR-positive breast cancer, and more.
During the Tuesday morning session, Thelma Brown, BSc, provided a patient perspective on the importance of increasing knowledge of and access to clinical trials.
Reuben Harris, PhD, explored the effects of the APOBEC protein family on genome evolution in metastatic breast cancer during the session Tuesday morning.
Ian Krop, MD, PhD, will moderate a Wednesday session examining the current landscape of antibody drug conjugates and what potential they might hold for cancer research and clinical practice.
This roundtable forum on Wednesday will offer early-career scientists a chance to interact with seasoned researchers on 15 different topics.